All Data
A partner for the pharma and biotech industries to improve patient outcomes & quality of life
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cassiopea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 04, 2020
Details:
Albany Molecular Research has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Risankizumab-rzaa
Therapeutic Area: Dermatology Product Name: Skyrizi
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
New head-to-head data from the IMMerge Phase 3b open-label study show SKYRIZI demonstrated superiority to COSENTYX at week 52, with 66 percent of SKYRIZI patients achieving completely clear skin (PASI 100) versus 40 percent of COSENTYX patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aminolevulinic Acid
Therapeutic Area: Dermatology Product Name: Ameluz
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
The application is supported by a phase I pharmacokinetics (PK) study for the treatment of actinic keratoses with three tubes of Ameluz®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Baricitinib
Therapeutic Area: Dermatology Product Name: Olumiant
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2020
Details:
New data for baricitinib for the treatment of moderate to severe atopic dermatitis showed that baricitinib 4-mg and 2-mg dose groups were able to maintain clear or almost clear skin response rates through the 68-week treatment period.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ixekizumab
Therapeutic Area: Dermatology Product Name: Taltz
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Taltz demonstrated sustained efficacy in adult psoriasis patients with baseline scalp, nail and palmoplantar (skin on the palms of the hands and soles of the feet) involvement with the following results at five years.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Presentations include data from open-label extension trials evaluating laboratory assessments in adults treated with Dupixent for up to three years and adolescents (aged 12 to 17 years) treated up to one year.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
Recommendation based on pivotal trial that showed Dupixent plus topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearance, itch and health-related quality of life, compared to TCS alone .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Guselkumab
Therapeutic Area: Dermatology Product Name: Tremfya
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
Data from VOYAGE 1 open-label, long-term extension study show sustained efficacy response rates at week 252 and no new safety signals. First study of an IL-23 inhibitor treatment to demonstrate safety and efficacy throughout a nearly five-year period of use.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: Zilxi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
Approved by the U.S. FDA, ZILXI is the first minocycline product of any form to be approved by the FDA for use in rosacea, a diverse skin condition that most commonly presents with symptoms such as deep facial redness, spider veins and acne-like inflammatory lesions.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
